Echo gets European go-ahead for needle-free Symphony trial; Norwegian nano-needles could force cellular delivery;

> Echo Therapeutics' ($ECTE) Symphony CGM System, a needle-free delivery device the company is developing for use as a glucose monitoring system, garnered acceptance from its Notified Body in Europe for a clinical trial plan. Release

> Nano-needles developed by Norwegian researchers may be used to force drugs into cells by impaling them from a tiny field of spikes. Article

> Arrowhead Research ($ARWR) filed with the FDA to begin a Phase I trial of its RNAi-based candidate for the treatment of hepatitis B. Release

> Drug-delivery company Acrux filed a lawsuit over claims that Perrigo Israel Pharmaceuticals infringed a patent of its delivery platform, Axiron. Release

> Swedish pharmaceutical company Oasmia has developed a combination cancer therapy with a unique drug-delivery system that allows the products to effectively act in tandem. WSJ report

Suggested Articles

Rutgers scientists have developed an anti-inflammatory drug delivery platform to better treat central nervous system injuries and disease.

Purdue's reformulated OxyContin may stop patients from snorting or injecting the drug, but it doesn't curb abuse overall, an FDA panel determined.

Roche is gearing up to launch an eye implant to make its Lucentis AMD drug easier to use. But the drugmaker has even bigger plans for the device.